Clinical trials
Phase 3 Atherosclerosis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 6 |
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 2 |
| 2021 | 4 |
| 2022 | 4 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
| Active, not recruiting | 9 |
| Recruiting | 6 |
| Terminated | 5 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Esperion Therapeutics, Inc. | 6 |
| Novartis Pharmaceuticals | 6 |
| Eli Lilly and Company | 4 |
| National Heart, Lung, and Blood Institute (NHLBI) | 4 |
| AstraZeneca | 3 |
| GlaxoSmithKline | 3 |
| NewAmsterdam Pharma | 3 |
| Abbott Medical Devices | 2 |
| Amgen | 2 |
| Brigham and Women's Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Atherosclerosis | 60 |
| Cardiovascular Diseases | 15 |
| Hypercholesterolemia | 14 |
| Hyperlipidemias | 8 |
| Peripheral Arterial Disease | 8 |
| Coronary Disease | 6 |
| Heart Diseases | 6 |
| Peripheral Vascular Diseases | 6 |
| Acute Coronary Syndrome | 5 |
| Hypertension | 5 |
Trials
Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.